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Inflammatory bowel diseases are associated with an increased risk of vascular complications. The most important are arterial
and venous thromboembolisms, which are considered as specific extraintestinal manifestations of inflammatory bowel diseases.
Among venous thromboembolism events, portal vein thrombosis has been described in inflammatory bowel diseases. We report
three cases of portal vein thrombosis occurring in patients with active inflammatory bowel disease. In two of them, hepatic abscess
was present. Furthermore, we performed a systematic review based on the clinical literature published on this topic.
1. Introduction
In inflammatory bowel diseases (IBD) there is a high inci-
dence of thromboembolic complications, as a consequence
of hypercoagulability status. Thrombosis of the splenic-
mesenteric-portal system is a rare event; however, due to
advances in diagnostic tools, many cases of mesenteric or
portal vein thrombosis have recently been described in IBD
patients; its incidence seems to be higher than among the
general population [1]. First of all we report three cases of
portal vein thrombosis in IBD patients; afterwards, we assess
the epidemiology, the clinical course, the diagnosis, and the
therapeutic approach of this complication of IBD, perform-
ing a systematic review based on the clinical literature.
An in-depth search in PubMed was based on four
search terms: “inflammatory bowel diseases” OR “Crohn’s
disease” OR “ulcerative colitis” AND “portal vein throm-
bosis” (MeSH terms). Review articles and case reports not
regarding this topic were excluded. The remaining articles
were categorised by topic and summarised.
Table 1 summarizes risk factors, treatment, and outcome
of portal vein thrombosis (PVT) in IBD patients reported in
the literature.
2. Case 1
A 66-year-old woman, with a 10-year diagnosis of inflam-
matory ileal Crohn’s disease (CD), on treatment with budes-
onide for active disease, was admitted to our unit for fever
with chills. There was no history of previous thromboem-
bolic events. Physical examination revealed tachycardia,
without any abdominal tenderness or masses; blood tests
showed leucocytosis (13000 white blood cells (WBC)/mm3),
thrombocytosis (360000 platelets/mm3), and increased ESR
(25mm/Ih) and PCR (18mg%); 3 blood cultures isolated
Gemella Haemolysans and Sphingomonas paucimobilis. Ultra-
sound (US) doppler and computer tomography (CT) scan
showed a small abscess in liver l and PVT extending to
the intrahepatic branches (Figure 1). Coagulation study did
not show any abnormalities (antithrombin, protein C and
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(i) Lupus anticoagulant (1)
(ii) Increased von Willebrand factor (2)
(iii) Increased homocysteine levels (4
with mutation of MTHFR-677-3 Ht)
Anticoagulant (4) Recanalization




Lupus anticoagulant + Ht for factor V
Leiden mutation (1 pt)
Oral anticoagulant NA
Ibele 1 (UC) None Oral anticoagulant Recanalization




Aguas 1 (CD) None Heparin Recanalization
Palkovist 1 (UD) None LMWH Portal cavernoma
Latzman 1 (CD) Ht for prothrombin-G20210A mutaion
Thrombobectomy + oral
anticoagulant Recanalization








Guglielmi 1 (CD) None Thrombolysis + LMWH Recanalization
Verna 1 (UC) Elevated FVII No therapy Atrophy of left hepatic lobe











NA Anticoagulation (8 pts)
Recanalization (5/13 pts)
Portal cavernoma (1/13 pt)
No change (7/13 pts)




Schafer 1 (CD) None Thrombolysis Recanalization
Farkas 1 (UC) None Oral anticoagulant Recanalization
Tsujikawa 1 (CD) None
Thrombolysis + heparin +
oral anticoagulant
Recanalization
Tung 1 (CD) None LMWH Recanalization








Mathieu 1 (CD) Acquired protein C deficiency LMWH Recanalization
Crowe 1 (CD) None Oral anticoagulant Recanalization
Brinberg 1 (CD) None Heparin Recanalization
Ht: heterozygosis, LMWH: low molecular weight heparin, IC: indeterminate colitis, UC: ulcerative colitis, CD: Crohn’s disease, and MTHFR: methyl-
tetrahydrofolate reductase.
S activity, plasma homocysteine level, PT, and aPTT were
normal) and no mutation was detected in factor II, V,
MTHFR, and PAI-I genes; antibody anticardiolipin and
antiphospholipid antibodies were negative; no mutation of
JAK-2 gene was found. The patient was treated with low-
molecular-weight heparin (LMWH) (1mg/kg/twice daily)
and imipenem on the basis of the blood culture results
for 3 weeks and then amoxicillin/clavulanic acid for further
2 weeks on the basis of the results of blood culture and
relative sensibility testing, with disappearance of fever. A
further US Doppler, performed one month after, showed
a complete patency of portal three and disappearance of
hepatic abscesses. LMWH was suspended after 3 months. At
the last outpatient control, the patient had optimal clinical
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Figure 1: Abdominal US showing a portal vein thrombosis extend-
ed to intrahepatic branches.
Figure 2: Residual portal cavernoma showed at CT scan.
and nutritional status, while US Doppler showed a residual
portal cavernoma, confirmed at CT scan (Figure 2).
3. Case 2
A 41-year-old woman with a family history of IBD was admi-
tted to our unit because of the onset of bloody diarrhoea.
There was no history of previous tromboembolic events.
Clinical examination showed fever (38.5◦C), hypotension
(80/50mmHg), tachycardia (115 beats/minute), tachyp-
nea, and abdominal distension without bowel movements;
blood tests showed leucocytosis (18000 white blood cells
(WBC)/mm3) and increased ESR (30mm/Ih) and PCR
(25mg%). An abdominal plain X-ray showed a dilation of
the transverse colon (diameter 6 cm), while an abdominal US
Doppler and CT scan showed ascites, complete thrombosis of
portal, mesenteric and splenic veins, and wall thickening of
the large bowel. The patient received steroids, ciprofloxacin,
and metronidazole. Coagulation study showed heterozygosis
for MTHFR gene mutation; antithrombin, protein C and S
activity, plasma homocysteine level, PT, and aPTT were nor-
mal; anticardiolipin and anti-phospholipid antibodies were
negative; no mutation of the JAK-2 gene was found. During
hospitalization the patient complained of acute dyspnoea,
Figure 3: CT scan showing gas in portal vein and a liver abscess.
with oxygen desaturation. A chest CT scan showed pul-
monary embolism. Treatment with LMWH (1mg/kg/twice
daily) was started, with progressive disappearance of res-
piratory complaints. Colonoscopy with biopsy, performed
after resolution of the colon dilation, diagnosed an ulcerative
pancolitis. The patient continued treatment with steroids at
tapering doses and started azathioprine. A US Doppler after
1 month showed complete recanalization of portal three.
LMWH was discontinued after 3 months. A US Doppler
control after 6 months showed patent portal tree.
4. Case 3
A 52-year-old male with a 20-year history of small bowel CD
resected twice, after recent detection of stenotic recurrence,
was admitted to our unit because of the onset of fever and
diarrhoea. No history of previous thromboembolic events
was present. Clinical examination showed fever (39◦C)
and painful abdominal distension; blood tests showed
leucocytosis (16000 white blood cells (WBC)/mm3) and
increased ESR (22mm/Ih) and PCR (24mg%). A CT
scan showed gas in the portal vein and a liver abscess
(Figure 3). Coagulation study (antithrombin, protein C and
S activity, plasma homocysteine level, PT, and aPTT) did
not show abnormalities and no mutations were detected in
factor II, V, MTHFR, and PAI-I genes; anticardiolipin and
antiphospholipid antibodies were negative; no mutation
of JAK-2 gene was found. The patient was treated with
ciprofloxacin and metronidazole and started LMWH
(1mg/kg/twice daily). After 4 weeks a CT scan showed patent
portal and mesenteric vein. After drainage of abdominal
abscesses, a surgical operation was performed for treatment
of strictures and fistula. LMWH was stopped after three
months. To date the patient is asymptomatic, with normal
and patent portal vein detected with periodic US controls.
5. Discussion
These three cases of portal thrombosis in IBD show that this
complication, despite its rarity, needs to be searched for in
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case of clinical suspicion, and that treatment with LMWH
leads to complete resolution of this complication.
Portal/mesenteric vein thrombosis, particularly in the
nonsurgical setting, is a rare complication in IBD patients
[2]. However, its incidence appears to be higher than in the
general population [1], linked to the high risk of venous
thromboembolism (VTE) in IBD [3–6].
Portal/mesenteric vein thrombosis in IBD, seen in a study
performed by the Mayo Clinic, was reported in 1.3% of
cases, with a mortality rate of 50% [7]. In our research,
including case reports, case series, letters to the editors, and
retrospective studies, we identified 82 cases of PVT in IBD
patients (Table 1). Bruining et al. [8] analyzed the records
of 357 consecutive patients with previously diagnosed CD
identified with computed tomography enterography. In
this series 6 patients (1.7%) had portal/mesenteric vein
thrombosis. In the study by Jackson et al. [9] among 9 IBD
patients, 8 subjects (4 with CD and 4 with UC) developed
mesenteric venous thrombosis (5 located in the SMV and 3
located in a branch of the portal vein). The mean time to
diagnosis of IBD to thrombosis was 24.6 ± 13.5 years, while
5 of the 9 patients developed mesenteric venous thrombosis
while their IBD was clinically in remission.
Maconi et al. [10], in their series, identified a prevalence
of 0.17%, with a mean time from the diagnosis of IBD to
the detection of IBD of 14.8 ± 6.6 years; in 4 patients the
diagnosis of PVT was made while their IBD (CD) was in
clinical remission, while 4 patients (2 UC patients and 2 CD
patients) had an active disease.
Portal thrombosis occurs more frequently in the setting
of abdominal surgery [1]. Fichera et al. [11] reported a 4.8%
incidence of superior mesenteric vein (SMV) thrombosis
among 83 patients undergoing colectomy for IBD.
PVT has been seen in UC patients following restorative
proctocolectomy [12–14]. In a retrospective study, PVT was
found in up to 45% of CT scans done after ileal pouch-anal
anastomosis (IPAA) for UC [12].
Portal/mesenteric vein thrombosis, and more generally
VTE, has been considered a manifestation which seems to
be related to intestinal inflammatory activity. Indeed, in
a diﬀerent chronic inflammatory disease like Rheumatoid
Arthritis, in which there is no intestinal inflammation, there
is no increased incidence of PVT compared to the general
population [15]. However, IBD patients in remission also
have an increased risk of VTE [3]. Hence additional factors,
other than inflammation, are probably involved [16].
The causes of portal/mesenteric thrombosis in IBD
are manifold; in most patients, recognized acquired pro-
thrombotic factors can be identified, such as inflammation,
immobilization, extent of colon disease, surgery, central
catheters, corticosteroids, and smoking [17–19].
On the other hand, thromboembolic complications in
IBD, such as PVT, may be associated with coagulation abnor-
malities, which are induced by chronic bowel inflammation
[15, 20]. Patients with IBD have increased platelet counts,
factor V and VIII levels, and fibrinogen levels and decreased
antithrombin III levels, all of which can increase the risk of
thrombosis [2, 20–26].
Several kinds of presentation of portal/mesenteric vein
thrombosis have been reported: IBD flares and sepsis (espe-
cially perioperative) have been more frequently described;
however, other rare modalities reported are variceal bleeding
(VB) and hepatic portal venous gas (HVPG) [27–32].
Thromboembolic complications of IBD are by no means
benign: the mortality rate has been reported to be as high
as 22%–25% [4, 7, 18]. As mentioned above, they can be
manifested at the onset of IBD, either during an IBD flare
or when the disease is in remission.
The most widely recognized pathophysiological factor of
PVT is the presence of ulceration and the loss of integrity
of the normal mucosa barrier in the bowel, which may
result in microbial invasion or translocation of the portal
vein system, with seeding in the parenchyma giving rise to
portal pylephlebitis—defined as septic thrombophlebitis of
the portal vein or of its tributaries—and PVT.
However, the presence of portal venous gas (PVG)
associated with PVT could be a rare but serious, even
catastrophic condition in IBD patients [33]; to date 21
cases of PVG associated with CD have been reported in the
scientific literature [34–37]. Among 182 case studies reported
by Chande et al. [38], patients with UC or CD comprised 4%
of the total.
PVG in IBD patients can be caused by mucosal damage
alone, or it can occur in combination with bowel distension,
sepsis, and invasion by gas-producing bacteria, or after
colonoscopy, upper gastrointestinal barium examination,
barium enema, or blunt abdominal trauma. PVG is not
always a surgical condition, and its treatment should be
based on the underlying disease and the patient’s current
clinical condition [35]. Although PVG itself is not a prog-
nostic indicator, PVG combined with pylephlebitis can be
regarded as an indicator of poor prognosis [35].
Regarding diagnosis of PVT in IBD patients, abdominal
US with colour Doppler proves crucial. However, CT scan is
more sensitive than US (which is more operator dependent
and gives results that are less reproducible than those of CT)
for detecting a thrombus within the splenic and mesenteric
veins, and therefore it should be the preferred imaging tech-
nique for detecting both thrombi and pericolonic abscesses,
especially in a setting of pylephlebitis [38]. A CT scan
also provides a better assessment of bowel viability and the
presence of a perforation, thus allowing one to work better
in selecting patients for conservative management [39].
Anticoagulants, such as LMWH and warfarin, are main-
stays of primary therapy, even in the setting of gastrointesti-
nal bleeding [17]. The duration of systemic anticoagulation is
not well established in the literature [40]. In the presence of
a congenital hypercoagulable state, consideration should be
given to lifelong systemic anticoagulation, although in other
prothrombotic conditions, a six-month course provides
adequate coverage. The use of anticoagulants in secondary
prevention is recommended but can be limited by continued
bleeding [41]. LMWH and devices such as inferior vena cava
filters have been used with success, according to the literature
[17, 38]. Both unfractionated heparin and LMWH have
also been studied for induction of remission in UC with-
out thromboembolic complications, but they have shown
Gastroenterology Research and Practice 5
no benefit over standard therapies alone [42]. However,
according to a recent Cochrane systematic review and meta-
analysis [38] there is evidence to suggest that LMWH may be
eﬀective for the treatment of active UC; when administered
by extended colon-release tablets, LMWH was more eﬀective
than placebo for treating outpatients with mild to moderate
disease. This benefit needs to be confirmed by further
randomized controlled trials. The same benefits were not
seen when LMWH was administered subcutaneously at
lower doses, while there is no evidence to support the use
of unfractionated heparin for the treatment of UC.
Other therapeutic approaches for acute portal/mesen-
teric vein thrombosis are, in extreme cases, surgical interven-
tions, thrombolysis, and intravascular thrombectomy devices
[43–51].
Minimizing modifiable risk factors is also a mainstay
of therapy. Smoking, oral contraceptives, and hormone
replacement therapy should be discontinued, and prolonged
immobility should be avoided as far as possible [17].
Summing up, whether or not to anticoagulate patients
with IBD and PVT remains controversial: certainly, antico-
agulation in the setting of active IBD may result in increased
haemorrhage risk. Those patients whose portal/mesenteric
vein thrombosis developed in the setting of significant
systemic inflammation should be treated on an individual
basis [14], just as preoperative prophylaxis in IBD patients
undergoing abdominal surgery should be further clarified.
In conclusion, portal/mesenteric vein thrombosis proves
to be more frequent in IBD patients than in healthy controls,
and among IBD patients this complication occurs more
frequently in the setting of abdominal surgery. Several
factors, inherited or acquired, related or not to IBD, seem
to be involved in its pathogenesis. Abdominal US is the
first-line technique to detect portal/mesenteric vein throm-
bosis, though, to date, CT scan remains the gold standard
technique. To date, there is no proved eﬀective treatment
for pylephlebitis and for portal/mesenteric vein thrombosis
in IBD, as the natural history of these conditions is not
well defined. However, in IBD patients, especially ones with
bloody diarrhoea, there is still a controversy as to whether
anticoagulation should be maintained lifelong, just as there
is insuﬃcient information about the timing and duration of
treatment with anticoagulation in the subset of IBD patients
without known coagulation disorders.
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